Latest On Ono Pharmaceutical Co., Ltd (OPHLF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 13:50 EST | News | Ono Pharmaceutical GAAP EPS of ¥230.79, revenue of ¥447.18B | N/A |  |
| 2023-01-30 21:47 EST | News | Ono Pharmaceutical GAAP EPS of ¥127.66, revenue of ¥216.7B | N/A | |
| 2022-12-14 09:34 EST | News | PrecisionLife and Ono Pharmaceutical enter multi-year collaboration | N/A | |
| 2022-08-01 19:29 EST | News | Ono Pharmaceutical GAAP EPS of ¥60.36, revenue of ¥106.72B | N/A | |
| 2022-06-28 15:03 EST | News | Fate, Ono expand team up on cancer immunotherapy program | N/A | |
| 2022-01-31 10:48 EST | News | Ono Pharmaceutical GAAP EPS of ¥129.59, revenue of ¥271.43B | N/A | |
| 2021-07-31 01:35 EST | News | Ono Pharmaceutical reports Q1 results | N/A | |
| 2021-07-31 01:35 EST | News | Ono Pharmaceutical Co., Ltd. 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2021-03-30 06:07 EST | Dividend | A dividend of $22.5 has been announced on May 12, 2020. It will be paid Nov 30, -0001 with an ex-dividend date of Mar 30, 2021. | Neutral | |
| 2021-02-10 23:29 EST | News | Bristol Myers announce new late-stage data for Opdivo/ Cabometyx combo in kidney cancer | N/A | |
| 2021-02-04 09:26 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-02 13:45 EST | Earnings Estimate | An EPS average of $43.10 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2020-11-26 23:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 02:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-02 09:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 15:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 07:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 14:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-03 10:26 EST | Earnings Estimate | An EPS average of $0.34 is estimated for the quarter ending on December 31, 2020. | Sell | |
| 2020-08-02 06:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 19:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 07:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 23:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 14:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 19:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 11:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-08 10:16 EST | Earnings Estimate | An EPS average of $31.40 is estimated for the quarter ending on September 30, 2020. | Buy | |
| 2020-07-01 18:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 02:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 06:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 08:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-02 10:23 EST | Earnings Estimate | An EPS average of $1.40 is estimated for the 2022 year. | Buy | |
| 2020-05-27 07:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-23 22:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 03:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 07:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 18:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-20 06:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-09 22:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-03 23:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-30 06:09 EST | Dividend | A dividend of $22.5 has been announced on May 9, 2019. It will be paid Jan 1, 1970 with an ex-dividend date of Mar 30, 2020. | Neutral | |
| 2020-03-25 22:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 06:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 00:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-22 01:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-22 01:41 EST | Earnings | Earnings have been released on March 31, 2019, with $0.15 earnings per share. | Sell | |
About Ono Pharmaceutical Co., Ltd (OPHLF):
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
General
- Name Ono Pharmaceutical Co., Ltd
- Symbol OPHLF
- Type Common Stock
- Exchange OTCGREY
- Currency USD
- Country USA
- Full Time Employees 3,560
- Fiscal Year EndMarch
- Web URLhttp://www.ono.co.jp
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $148.77
- Next Year EPS Estimate $175.05
- Next Quarter EPS Estimate $0.25
- Profit Margin 25%
- Return on Assets 9%
- Return on Equity 12%
- Revenue Per Share $0
- Gross Profit 213.36 billion
- Quarterly Earnings Growth 10.7%
ESG Rating
Highlights
- Market Capitalization 15.18 billion
- PEG Ratio 40586.9
Share Statistics
- Shares Outstanding 514.12 million
- Shares Float 464.86 million
- % Held by Insiders 1792%
- % Held by Institutions 33.81%
Technicals
- Beta 0.48
- 52 Week High $31
- 52 Week Low $18
- 50 Day Moving Average 29.26
- 200 Day Moving Average 28.37
Dividends
- Dividend Date 2018-06-25
- ExDividend Date N/A
- Dividend Yield 0%
Ono Pharmaceutical Co., Ltd (OPHLF) Dividend Calendar:
OPHLF's last dividend payment was made to shareholders on June 25, 2018.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Ono Pharmaceutical Co., Ltd (OPHLF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $N/A | $53.37 | $32.81 | 62.66% |
| 2020-09-30 | 2020-12-31 | $N/A | $0.52 | $31.40 | -98.35% |
| 2020-06-30 | 2020-09-30 | $N/A | $0.35 | $35.40 | -99.02% |
| 2020-03-31 | 2020-06-30 | $N/A | $0.40 | $17.21 | -97.68% |
| 2019-12-31 | 2020-03-31 | $702.33 million | $0.15 | $29.14 | -99.5% |
| 2019-09-30 | 2019-12-31 | $694.17 million | $0.35 | $26.29 | -98.67% |
| 2019-06-30 | 2019-09-30 | $683.25 million | $0.30 | $27.20 | -98.89% |
| 2019-03-31 | 2019-06-30 | $587.64 million | $0.30 | $18.20 | -98.38% |
| 2018-12-31 | 2019-03-31 | $719.16 million | $0.15 | $36.20 | -99.59% |
| 2018-09-30 | 2018-12-31 | $642.12 million | $0.25 | $25.80 | -99.02% |
| 2018-06-30 | 2018-09-30 | $642.43 million | $0.23 | $27.80 | -99.16% |
| 2018-03-31 | 2018-06-30 | $578.55 million | $0.27 | $7.80 | -96.57% |
| 2017-12-31 | 2018-03-31 | $702.37 million | $0.16 | $24.80 | -99.35% |
| 2017-09-30 | 2017-12-31 | $536.81 million | $0.35 | $15.00 | -97.67% |
| 2017-06-30 | 2017-09-30 | $542.03 million | $0.16 | $21.30 | -99.24% |
| 2017-03-31 | 2017-06-30 | $55.95 billion | $0.20 | ||
| 2016-12-31 | 2017-03-31 | $0.23 | $51.10 | -99.56% | |
| 2016-09-30 | 2016-12-31 | $0.31 | $21.90 | -98.57% | |
| 2016-06-30 | 2016-09-30 | $0.18 | $26.60 | -99.34% | |
| 2016-03-31 | 2016-06-30 | $0.25 | $7.20 | -96.51% | |
| 2015-12-31 | 2016-03-31 | $0.10 | $5.68 | -98.29% | |
| 2015-09-30 | 2015-12-31 | $0.11 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $0.04 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | $0.15 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | -$0.04 | $8.98 | -100.48% | |
| 2014-09-30 | 2014-12-31 | $0.20 | $1.06 | -81.54% | |
| 2014-06-30 | 2014-09-30 | $0.01 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $0.05 | $6.04 | -99.1% | |
| 2013-12-31 | 2014-03-31 | $0.04 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.15 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.07 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $0.12 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.13 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $0.14 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | $0.06 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $0.20 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.15 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.23 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $0.00 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.20 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.12 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.22 | $0.00 |
Ono Pharmaceutical Co., Ltd (OPHLF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Ono Pharmaceutical Co., Ltd (OPHLF) Chart:
Ono Pharmaceutical Co., Ltd (OPHLF) News:
Below you will find a list of latest news for Ono Pharmaceutical Co., Ltd (OPHLF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Ono Pharmaceutical Co., Ltd (OPHLF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Ono Pharmaceutical Co., Ltd (OPHLF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2016-10-17 | F-6 | Registration of American Depository Receipt shares, not immediately effective | https://www.sec.gov/Archives/edgar/data/940821/000095012716000087/0000950127-16-000087-index.htm |
| 2017-04-26 | F-6/A | Registration of American Depository Receipt shares, not immediately effective | https://www.sec.gov/Archives/edgar/data/940821/000095012717000017/0000950127-17-000017-index.htm |
| 2017-05-22 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/940821/000095012717000026/0000950127-17-000026-index.htm |
| 2008-10-31 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/940821/000101915508000735/0001019155-08-000735-index.htm |
| 2014-05-23 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/940821/000101915514000206/0001019155-14-000206-index.htm |
| 2016-05-24 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/940821/000101915516000592/0001019155-16-000592-index.htm |
| 2008-10-10 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/940821/000110465908063300/0001104659-08-063300-index.htm |
| 2009-02-20 | RW | Registration Withdrawal Request | https://www.sec.gov/Archives/edgar/data/940821/000115955409000005/0001159554-09-000005-index.htm |
| 2015-07-24 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/940821/000119380515001248/0001193805-15-001248-index.htm |
| 2016-03-30 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/940821/000119380516002953/0001193805-16-002953-index.htm |
| 2016-08-25 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/940821/000119380516003823/0001193805-16-003823-index.htm |
| 2017-09-29 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/940821/000119380517002942/0001193805-17-002942-index.htm |
| 2019-11-22 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/940821/000119380519001593/0001193805-19-001593-index.htm |
| 2017-04-26 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/940821/999999999517000962/9999999995-17-000962-index.htm |